ReKUPFFERate
Financiado
Investigating if recuperating hepatic macrophage numbers and functions in chroni...
Investigating if recuperating hepatic macrophage numbers and functions in chronic fibrosis can limit the incidence and severity of infections
Liver fibrosis is the build-up of scar tissue resulting in impaired liver function. It can have different causes including alcohol abuse, obesity and viral hepatitis. For reasons that we do not fully understand, patients with fibr...
Liver fibrosis is the build-up of scar tissue resulting in impaired liver function. It can have different causes including alcohol abuse, obesity and viral hepatitis. For reasons that we do not fully understand, patients with fibrosis (termed cirrhosis) are more susceptible to infections. In fact, 50% of hospitalized patients with liver cirrhosis and infection die, highlighting the scale of this problem. Macrophages (MFs) are immune cells present in every tissue of the body that function to eliminate pathogens. In the liver, one subset of MFs, the Kupffer cells (KCs) are perfectly equipped with scavenger and pathogen recognition receptors to do this. Moreover, they are positioned in the bloodstream meaning they are one of the first cells to sense and respond to circulating pathogens although their precise roles have not yet been elucidated. In cirrhosis, KCs are reduced in number, being replaced by distinct MF subtypes, including a population termed lipid-associated MFs (LAMs). Preliminary data from the host lab demonstrate that both KCs and LAMs from the cirrhotic liver respond less efficiently to infection when compared with their healthy counterparts. Thus, I hypothesize that the altered MF landscape in cirrhosis and fibrosis is one mechanism driving the increased susceptibility and exacerbated responses to infection in these patients. Here, I aim to test this hypothesis by examining how the different MFs respond to infection in the presence and absence of fibrosis. Using novel mouse models specifically targeting the distinct MF populations, coupled with ex vivo cultures of human hepatic MFs, I will tease apart the mechanisms through which MFs exert their effects and attempt to manipulate these to recuperate normal MF numbers and functions potentially uncovering novel therapeutic approaches to limit infection and improve cirrhotic patient health.
ver más
Duración del proyecto: 26 meses
Fecha Inicio: 2023-07-14
Fecha Fin: 2025-09-30
Fecha Fin: 2025-09-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-07-14
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-MSCA-2022-PF-01-01:
MSCA Postdoctoral Fellowships 2022
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
176K€
Líder del proyecto
VIB VZW
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5